FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036354112> ?p ?o ?g. }

• W3036354112 endingPage "508.e2" @default.
• W3036354112 startingPage "498" @default.
• W3036354112 abstract "Background The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non–small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%. Patients and Methods We previously conducted a multicenter retrospective analysis in patients with treatment-naive metastatic NSCLC and a PD-L1 expression of ≥ 50% receiving first-line pembrolizumab. Here, we report the results of the irAE analysis and the potential correlation between irAEs and clinical outcomes. Results A total of 1010 patients were included in this analysis; after a 6-week landmark selection, 877 (86.8%) patients were included in the efficacy analysis. Any grade irAEs (P < .0001), grade 3/4 irAEs (P = .0025), leading to discontinuation irAEs (P = .0144), multiple-site and single-site irAEs (P < .0001), cutaneous irAEs (P = .0001), endocrine irAEs (P = .0227), pulmonary irAEs (P = .0479), and rheumatologic irAEs (P = .0018) were significantly related to a higher objective response rate. Any grade irAEs (P < .0001), single-site irAEs (P < .0001), multiple-site irAEs (P = .0005), cutaneous irAEs (P = .0042), endocrine irAEs (P < .0001), gastrointestinal irAEs (P = .0391), and rheumatologic irAEs (P = .0086) were significantly related to progression-free survival. Any grade irAEs (P < .0001), single-site irAEs (P < .0001), multiple-site irAEs (P = .0003), cutaneous irAEs (P = .0002), endocrine irAEs (P = .0001), and rheumatologic irAEs (P = .0214) were significantly related to overall survival. Conclusions This study confirms the feasibility and the safety of first-line, single-agent pembrolizumab, in a large, real-world cohort of patients with NSCLC with PD-L1 expression ≥ 50%. The occurrence of irAEs may be a surrogate of clinical activity and improved outcomes in this setting." @default.
• W3036354112 created "2020-06-25" @default.
• W3036354112 creator A5000995161 @default.
• W3036354112 creator A5001928949 @default.
• W3036354112 creator A5002745641 @default.
• W3036354112 creator A5003880441 @default.
• W3036354112 creator A5004048756 @default.
• W3036354112 creator A5004581470 @default.
• W3036354112 creator A5004680827 @default.
• W3036354112 creator A5006525898 @default.
• W3036354112 creator A5011289747 @default.
• W3036354112 creator A5011458340 @default.
• W3036354112 creator A5012176145 @default.
• W3036354112 creator A5012937808 @default.
• W3036354112 creator A5013441605 @default.
• W3036354112 creator A5013768705 @default.
• W3036354112 creator A5013910269 @default.
• W3036354112 creator A5019053015 @default.
• W3036354112 creator A5020344479 @default.
• W3036354112 creator A5021158045 @default.
• W3036354112 creator A5021264126 @default.
• W3036354112 creator A5021477463 @default.
• W3036354112 creator A5022098963 @default.
• W3036354112 creator A5022151942 @default.
• W3036354112 creator A5023759909 @default.
• W3036354112 creator A5025890835 @default.
• W3036354112 creator A5026153195 @default.
• W3036354112 creator A5027420799 @default.
• W3036354112 creator A5030450694 @default.
• W3036354112 creator A5030465858 @default.
• W3036354112 creator A5032477448 @default.
• W3036354112 creator A5032833091 @default.
• W3036354112 creator A5033124196 @default.
• W3036354112 creator A5033351253 @default.
• W3036354112 creator A5041434581 @default.
• W3036354112 creator A5041977580 @default.
• W3036354112 creator A5042730999 @default.
• W3036354112 creator A5042989547 @default.
• W3036354112 creator A5047645174 @default.
• W3036354112 creator A5048540733 @default.
• W3036354112 creator A5048627770 @default.
• W3036354112 creator A5051933262 @default.
• W3036354112 creator A5052937372 @default.
• W3036354112 creator A5053015211 @default.
• W3036354112 creator A5054617465 @default.
• W3036354112 creator A5056089850 @default.
• W3036354112 creator A5057105147 @default.
• W3036354112 creator A5058643588 @default.
• W3036354112 creator A5058760175 @default.
• W3036354112 creator A5060954139 @default.
• W3036354112 creator A5062065961 @default.
• W3036354112 creator A5063263109 @default.
• W3036354112 creator A5063424146 @default.
• W3036354112 creator A5064542874 @default.
• W3036354112 creator A5065057377 @default.
• W3036354112 creator A5067404851 @default.
• W3036354112 creator A5067754025 @default.
• W3036354112 creator A5067835080 @default.
• W3036354112 creator A5070073727 @default.
• W3036354112 creator A5071422886 @default.
• W3036354112 creator A5071515814 @default.
• W3036354112 creator A5072776768 @default.
• W3036354112 creator A5073186349 @default.
• W3036354112 creator A5078839479 @default.
• W3036354112 creator A5078917021 @default.
• W3036354112 creator A5080124352 @default.
• W3036354112 creator A5081483832 @default.
• W3036354112 creator A5083548352 @default.
• W3036354112 creator A5085432815 @default.
• W3036354112 creator A5086247944 @default.
• W3036354112 creator A5087434482 @default.
• W3036354112 creator A5090705680 @default.
• W3036354112 creator A5091765229 @default.
• W3036354112 date "2020-11-01" @default.
• W3036354112 modified "2023-10-12" @default.
• W3036354112 title "Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes" @default.
• W3036354112 cites W2019607817 @default.
• W3036354112 cites W2046767112 @default.
• W3036354112 cites W2159665192 @default.
• W3036354112 cites W2289841322 @default.
• W3036354112 cites W2527905628 @default.
• W3036354112 cites W2746991247 @default.
• W3036354112 cites W2754877046 @default.
• W3036354112 cites W2759963646 @default.
• W3036354112 cites W2786816161 @default.
• W3036354112 cites W2795152269 @default.
• W3036354112 cites W2796582438 @default.
• W3036354112 cites W2892640821 @default.
• W3036354112 cites W2893221436 @default.
• W3036354112 cites W2903486314 @default.
• W3036354112 cites W2910245285 @default.
• W3036354112 cites W2915650040 @default.
• W3036354112 cites W2917602796 @default.
• W3036354112 cites W2935577863 @default.
• W3036354112 cites W2940759533 @default.
• W3036354112 cites W2942467666 @default.
• W3036354112 cites W2943701399 @default.
• W3036354112 cites W2965778028 @default.

• next